BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3:3780-817. [PMID: 31770441 DOI: 10.1182/bloodadvances.2019000812] [Cited by in Crossref: 154] [Cited by in F6Publishing: 150] [Article Influence: 77.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Chen L, Zhang F, Lu H, Chen X, Wen A, Luo J, Hu Y, Wang Y, Niu T, Zheng L. First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2020;18:3053-60. [PMID: 32865293 DOI: 10.1111/jth.15078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Michel M. Adult Evans' Syndrome. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.12.004] [Reference Citation Analysis]
3 Yu TS, Wang HY, Zhao YJ, Yu YF, Hou Y, Liu S, Han PP, Ni XF, Ji XB, Peng J, Liu XG, Hou M. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv 2021;5:4087-101. [PMID: 34507351 DOI: 10.1182/bloodadvances.2020003860] [Reference Citation Analysis]
4 Grainger JD, Kühne T, Hippenmeyer J, Cooper N. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. Ann Hematol 2021;100:2143-54. [PMID: 34308495 DOI: 10.1007/s00277-021-04590-0] [Reference Citation Analysis]
5 Ebbo M, Rivière E, Godeau B. [Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later]. Rev Med Interne 2021;42:38-45. [PMID: 32712041 DOI: 10.1016/j.revmed.2020.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Singh A, Uzun G, Bakchoul T. Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. J Clin Med 2021;10:789. [PMID: 33669423 DOI: 10.3390/jcm10040789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kewan T, Almhana F, Schwartzman L, Daw H, Haddad A. COVID-19 patient with immune thrombocytopenic purpura. Int J Lab Hematol 2020;42:e260-2. [PMID: 32786138 DOI: 10.1111/ijlh.13303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Semple JW, Rebetz J, Maouia A, Kapur R. An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol 2020;27:423-9. [PMID: 32868673 DOI: 10.1097/MOH.0000000000000612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
9 Yen H, Lin C, Lin M, Hsu Y, Lin Y. Prenatal Exposure to Air Pollution and Immune Thrombocytopenia: A Nationwide Population-Based Cohort Study. Front Pediatr 2022;10:837101. [DOI: 10.3389/fped.2022.837101] [Reference Citation Analysis]
10 Schifferli A, Heiri A, Imbach P, Holzhauer S, Seidel MG, Nugent D, Michel M, Kühne T. Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Adv 2021;5:1617-26. [PMID: 33710335 DOI: 10.1182/bloodadvances.2020003004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lozano ML, Sanz MA, Vicente V; Grupo Español de PTI (GEPTI). Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia. Med Clin (Barc) 2021;157:191-8. [PMID: 34088525 DOI: 10.1016/j.medcli.2021.03.017] [Reference Citation Analysis]
12 Gilreath J, Lo M, Bubalo J. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. Drugs 2021;81:1285-305. [PMID: 34160821 DOI: 10.1007/s40265-021-01553-7] [Reference Citation Analysis]
13 Swan D, Newland A, Rodegheiro F, Thachil J. Thrombosis in immune thrombocytopenia - current status and future perspectives. Br J Haematol 2021;194:822-34. [PMID: 33822358 DOI: 10.1111/bjh.17390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Küster O, Schmohl J, Greiner J, Storz MA. Severe immune thrombocytopenia following diphtheria, tetanus, pertussis and polio vaccination in a 36-year-old Caucasian woman: a case report. Eur J Med Res 2022;27:63. [PMID: 35505368 DOI: 10.1186/s40001-022-00686-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tu X, Xue A, Wu S, Jin M, Zhao P, Zhang H. Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia. Front Pharmacol 2021;12:795884. [PMID: 35153753 DOI: 10.3389/fphar.2021.795884] [Reference Citation Analysis]
16 Meyer O, Wong RSM, Khelif A, Stankovic M, Maier J, Saleh MN, Bussel JB. Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study. Br J Haematol 2021. [PMID: 34458977 DOI: 10.1111/bjh.17800] [Reference Citation Analysis]
17 Raso S, Napolitano M, Arrigo G, Reale F, Lucchesi A, Silimbani P, Maggio A, Calvaruso G, Consoli U, Mannina D, Giordano G, Santoro M, Accurso V, Siragusa S. Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis. Ann Hematol 2021;100:653-9. [PMID: 33495923 DOI: 10.1007/s00277-021-04438-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Revuz S, Vernier N, Saadi L, Campagne J, Poussing S, Maurier F. Immune Thrombocytopenic Purpura in Patients with COVID-19. Eur J Case Rep Intern Med 2020;7:001751. [PMID: 32665935 DOI: 10.12890/2020_001751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mageau A, Terriou L, Ebbo M, Souchaud-Debouverie O, Orvain C, Graveleau J, Lega JC, Ruivard M, Viallard JF, Cheze S, Dossier A, Bonnotte B, Perlat A, Gobert D, Costedoat-Chalumeau N, Jeandel PY, Dernoncourt A, Michel M, Godeau B, Comont T. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment. Am J Hematol 2022;97:10-7. [PMID: 34661954 DOI: 10.1002/ajh.26378] [Reference Citation Analysis]
20 Agarwal N, Mangla A. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Ther Adv Hematol 2021;12:20406207211001139. [PMID: 33796239 DOI: 10.1177/20406207211001139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Provan D, Newland AC. Investigational drugs for immune thrombocytopenia. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2075340] [Reference Citation Analysis]
22 Metallidis S, Gioula G, Papaioannou M, Exindari M, Chrysanthidis T, Tsachouridou O, Mimtsoudis I, Christoforidi M, Zempekakis P, Papa-Konidari A, Tsiodras S. Immune Thrombocytopenia in a Patient Recovering From COVID-19. Hemasphere 2020;4:e419. [PMID: 33134859 DOI: 10.1097/HS9.0000000000000419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tang Y, Chen J, Liu Q, Chu T, Pan T, Liang J, He XF, Chen F, Yang T, Ma X, Wu X, Hu S, Cao X, Hu X, Hu J, Liu Y, Qi J, Shen Y, Ruan C, Han Y, Wu D. Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial. Blood Adv 2021;5:1250-8. [PMID: 33646303 DOI: 10.1182/bloodadvances.2020002790] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kim TJ, Lee H. Benefits of Helicobacter pylori Eradication on Extragastric Diseases. Korean J Helicobacter Up Gastrointest Res 2021;21:275-86. [DOI: 10.7704/kjhugr.2021.0041] [Reference Citation Analysis]
25 Cooper N, Bird R, Chinthammitr Y, George B, Stentoft J, Tomiyama Y, Zaja F, Hokland P. How I treat immune thrombocytopenia - a global view. Br J Haematol 2021;193:1076-86. [PMID: 33570179 DOI: 10.1111/bjh.17324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Karakas D, Xu M, Ni H. GPIbα is the driving force of hepatic thrombopoietin generation. Res Pract Thromb Haemost 2021;5:e12506. [PMID: 33977209 DOI: 10.1002/rth2.12506] [Reference Citation Analysis]
27 Bienz M, Morin-Ben Abdallah S, Greenaway C, Pelletier JS, Caplan S, Knecht H. Severe Cystic Echinococcosis-Associated Immune Thrombocytopenic Purpura: A Case Report. J Hematol 2021;10:71-5. [PMID: 34007368 DOI: 10.14740/jh789] [Reference Citation Analysis]
28 Choi PY, Merriman E, Bennett A, Enjeti AK, Tan CW, Goncalves I, Hsu D, Bird R. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Med J Aust 2021. [PMID: 34628650 DOI: 10.5694/mja2.51284] [Reference Citation Analysis]
29 Park YH. Diagnosis and management of thrombocytopenia in pregnancy. Blood Res 2022;57:79-85. [PMID: 35483931 DOI: 10.5045/br.2022.2022068] [Reference Citation Analysis]
30 Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]. Zhonghua Xue Ye Xue Za Zhi 2020;41:617-23. [PMID: 32942813 DOI: 10.3760/cma.j.issn.0253-2727.2020.08.001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Dierickx D, Neefs J. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients. Expert Opin Pharmacother 2022. [PMID: 35621338 DOI: 10.1080/14656566.2022.2082283] [Reference Citation Analysis]
32 Qi J, Zheng L, Hu B, Zhou H, He Q, Liu H, Kawai H, Yang R. Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial. Clin Pharmacol Drug Dev 2021. [PMID: 34921514 DOI: 10.1002/cpdd.1059] [Reference Citation Analysis]
33 Santacruz JC, Mantilla MJ, Rueda I, Pulido S, Rodriguez-salas G, Londono J. A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus. [DOI: 10.7759/cureus.22938] [Reference Citation Analysis]
34 Porcelijn L, Schmidt DE, Oldert G, Hofstede-van Egmond S, Kapur R, Zwaginga JJ, de Haas M. Evolution and Utility of Antiplatelet Autoantibody Testing in Patients with Immune Thrombocytopenia. Transfus Med Rev 2020;34:258-69. [PMID: 33046350 DOI: 10.1016/j.tmrv.2020.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Wang RT, Liu XG, Hou Y, Hou M. [A physician-patient survey for primary immune thrombocytopenia: Chinese subgroup analysis of I-WISh International Survey]. Zhonghua Xue Ye Xue Za Zhi 2021;42:369-75. [PMID: 34218578 DOI: 10.3760/cma.j.issn.0253-2727.2021.05.004] [Reference Citation Analysis]
36 Subtil SFC, Mendes JMB, Areia ALFA, Moura JPAS. Update on Thrombocytopenia in Pregnancy. Rev Bras Ginecol Obstet 2020;42:834-40. [PMID: 33348401 DOI: 10.1055/s-0040-1721350] [Reference Citation Analysis]
37 Maitland HS. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy. Am J Case Rep 2021;22:e933788. [PMID: 34862358 DOI: 10.12659/AJCR.933788] [Reference Citation Analysis]
38 Doobaree IU, Conway K, Miah H Mr, Miah A, Makris M, Hill Q, Cooper N, Bradbury C, Newland A, Provan D, McDonald V; UK adult ITP registry. Incidence of adult primary immune thrombocytopenia in England-An update. Eur J Haematol 2022. [PMID: 35670140 DOI: 10.1111/ejh.13803] [Reference Citation Analysis]
39 Williams EL, Stimpson ML, Lait PJP, Schewitz-Bowers LP, Jones LV, Dhanda AD, Lee RWJ, Bradbury CA. Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14++ CD16+ intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype. Br J Haematol 2021;192:375-84. [PMID: 33338291 DOI: 10.1111/bjh.17205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Roumier M, Le Burel S, Audia S, Chauchet A, Gousseff M, Hamidou M, Liferman F, Moulis G, Lioger B, Galicier L, Ebbo M, London J, Poutrel S, Terriou L, Zarrouk V, Michel M, Godeau B, Mahevas M. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. Am J Hematol 2021;96:E43-6. [PMID: 33125750 DOI: 10.1002/ajh.26040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
41 Qureshi K, Bonder A. Thrombopoietin-receptor agonists in perioperative treatment of patients with chronic liver disease. World J Meta-Anal 2020; 8(3): 220-232 [DOI: 10.13105/wjma.v8.i3.220] [Reference Citation Analysis]
42 Yang J, Liang M. Risk factors for pregnancy morbidity in women with antiphospholipid syndrome. J Reprod Immunol 2021;145:103315. [PMID: 33845396 DOI: 10.1016/j.jri.2021.103315] [Reference Citation Analysis]
43 Kanda RG, Niero-melo L, Domingues MAC, Oliveira CC. Impact of reticulin stain in clinical outcome of Immune Thrombocytopenic Purpura (ITP): a pathologist perspective. Surg Exp Pathol 2022;5. [DOI: 10.1186/s42047-022-00108-8] [Reference Citation Analysis]
44 Collins EC, Carr MJ, Kim JS, Lewis J Jr, Maleque N, Desai K, Chen L, Sevransky J, Gaddh M, Rouphael N, Hubbard J, Pendley AM. Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination. J Am Coll Emerg Physicians Open 2021;2:e12531. [PMID: 34568869 DOI: 10.1002/emp2.12531] [Reference Citation Analysis]
45 Lorenzo-Villalba N, Zulfiqar AA, Auburtin M, Schuhmacher MH, Meyer A, Maouche Y, Keller O, Andres E. Thrombocytopenia in the Course of COVID-19 Infection. Eur J Case Rep Intern Med 2020;7:001702. [PMID: 32523922 DOI: 10.12890/2020_001702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
46 Huang QS, Zhu XL, Qu QY, Liu X, Zhang GC, Su Y, Chen Q, Liu FQ, Sun XY, Liang MY, Liu Y, Jiang M, Liu H, Feng R, Yao HX, Zhang L, Qian SX, Yang TH, Zhang JY, Shen XL, Yang LH, Hu JD, Huang RW, Jiang ZX, Wang JW, Zhang HY, Xiao Z, Zhan SY, Liu HX, Chang YJ, Jiang Q, Jiang H, Lu J, Xu LP, Zhang XH, Yin CH, Wang JL, Huang XJ, Zhang XH. Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. Am J Hematol 2021;96:561-70. [PMID: 33606900 DOI: 10.1002/ajh.26134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Yang Y, Tang Z, Ji J, Yang C, Chen M, Han B. Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study. Front Oncol 2021;11:721764. [PMID: 34778037 DOI: 10.3389/fonc.2021.721764] [Reference Citation Analysis]
48 Meyer O, Richter H, Lebioda A, Schill M. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany. Hematology 2021;26:697-708. [PMID: 34547980 DOI: 10.1080/16078454.2021.1974203] [Reference Citation Analysis]
49 Narmanli M, Gürsoy V, Ali R, Özen Y. Effectiveness and Reliability of Splenectomy in Chronic Idiopathic Thrombocytopenia. Turkish Journal of Internal Medicine 2020;2:73-7. [DOI: 10.46310/tjim.767946] [Reference Citation Analysis]
50 Lafaurie M, Maquet J, Baricault B, Ekstrand C, Christiansen CF, Linder M, Bahmanyar S, Nørgaard M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. Br J Haematol 2021. [PMID: 34386974 DOI: 10.1111/bjh.17709] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Gómez-Almaguer D, Rojas-Guerrero EA, Gómez-De León A, Colunga-Pedraza PR, Jaime-Pérez JC. Alternatives for managing patients with newly diagnosed immune thrombocytopenia: a narrative review. Expert Rev Hematol 2022. [PMID: 35615916 DOI: 10.1080/17474086.2022.2082936] [Reference Citation Analysis]
52 Cohen I, Goldvaser H, Kirgner I, Leader A, Raanani P, Isakov O, Shepshelovich D. Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Ann Hematol 2021;100:2879-87. [PMID: 34613438 DOI: 10.1007/s00277-021-04669-8] [Reference Citation Analysis]
53 Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol 2022. [PMID: 35179784 DOI: 10.1111/bjh.18081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Sandvad M, Pedersen EA, Frederiksen H, Mannering N. Risk of infection in adult patients with primary immune thrombocytopenia (ITP): a systematic review. Expert Rev Hematol 2021;14:961-74. [PMID: 34487679 DOI: 10.1080/17474086.2021.1976635] [Reference Citation Analysis]
55 Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020;135:472-90. [PMID: 31756253 DOI: 10.1182/blood.2019003599] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
56 Ozkok S, Kaygusuz Atagunduz I, Kara O, Sezgin A, Ozgumus T, Gecgel F, Firatli Tuglular T, Toptas T. Splenectomy in İmmune Thrombocytopenia: A Retrospective Analysis of 25-Year Follow-up Data from a Tertiary Health Clinic. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01467-0] [Reference Citation Analysis]
57 Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol 2021;14:37. [PMID: 33632264 DOI: 10.1186/s13045-021-01047-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Wong JSY, Kang JH, Maw KZ. Acute immune thrombocytopenic purpura post first dose of COVID-19 vaccination. Postgrad Med J 2021:postgradmedj-2021-140947. [PMID: 34446449 DOI: 10.1136/postgradmedj-2021-140947] [Reference Citation Analysis]
59 Kapur R. Fine‐tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second‐line therapy. Br J Haematol 2020;190:817-8. [DOI: 10.1111/bjh.16958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Tjønnfjord E, Holme PA, Darne B, Khelif A, Waage A, Michel M, Ben Romdhan N, Ghanima W. Long‐term outcomes of patients treated with rituximab as second‐line treatment for adult immune thrombocytopenia – Follow‐up of the RITP study. Br J Haematol 2020;191:460-5. [DOI: 10.1111/bjh.16672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Cuker A, Liebman HA. Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern. Res Pract Thromb Haemost 2021;5:e12592. [PMID: 34466771 DOI: 10.1002/rth2.12592] [Reference Citation Analysis]
62 Mytych DT, Park JK, Kim J, Barger TE, Boshier A, Jawa V, Kuter DJ. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. Br J Haematol 2020;190:923-32. [PMID: 32311075 DOI: 10.1111/bjh.16658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chen F, McDonald V, Newland A. Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). Expert Opin Biol Ther 2021;:1-11. [PMID: 34313512 DOI: 10.1080/14712598.2021.1960979] [Reference Citation Analysis]
64 İncaman D. Management of Immune Thrombocytopenic Patient Associated with COVID-19 Viral Infection: A Case Series. Turkish Journal of Internal Medicine. [DOI: 10.46310/tjim.1009709] [Reference Citation Analysis]
65 Chawla S, Barman P, Tyagi R, Jindal AK, Sharma S, Rawat A, Singh S. Autoimmune Cytopenias in Common Variable Immunodeficiency Are a Diagnostic and Therapeutic Conundrum: An Update. Front Immunol 2022;13:869466. [DOI: 10.3389/fimmu.2022.869466] [Reference Citation Analysis]
66 Godeau B. [Immune thrombocytopenia: state of the art and perspectives]. Rev Med Interne 2021;42:1-2. [PMID: 33261888 DOI: 10.1016/j.revmed.2020.11.005] [Reference Citation Analysis]
67 Elalfy MS, Eltonbary KYEM, El Ghamry IR, Elalfy O, Wahid M, Badr M, Hassan T, Mansour A, Meabed M, El-Hawy M, Youssry I, Abd Elhady M, Elshanshory M, Elsayh K, Hassab HM. Intracranial hemorrhage in primary immune thrombocytopenia (ITP): 20 years' experience in pediatrics. Eur J Pediatr 2021;180:1545-52. [PMID: 33452569 DOI: 10.1007/s00431-020-03923-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Cuker A, Despotovic JM, Grace RF, Kruse C, Lambert MP, Liebman HA, Lyons RM, McCrae KR, Pullarkat V, Wasser JS, Beenhouwer D, Gibbs SN, Yermilov I, Broder MS. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost 2021;5:69-80. [PMID: 33537531 DOI: 10.1002/rth2.12457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Ayad N, Grace RF, Al-Samkari H. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. Pediatr Blood Cancer 2021;:e29447. [PMID: 34962697 DOI: 10.1002/pbc.29447] [Reference Citation Analysis]
70 Sun S, Urbanus RT, ten Cate H, de Groot PG, de Laat B, Heemskerk JWM, Roest M. Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells 2021;10:3386. [DOI: 10.3390/cells10123386] [Reference Citation Analysis]
71 Liu XG, Hou M. [American Society of Hematology 2019 guidelines and updated international consensus report for adult primary immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi 2020;41:441-5. [PMID: 32654454 DOI: 10.3760/cma.j.issn.0253-2727.2020.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Chaudhury B, Grainger J. UK second-line paediatric primary ITP therapy analysis. Arch Dis Child 2021;106:929-31. [PMID: 33597180 DOI: 10.1136/archdischild-2020-320646] [Reference Citation Analysis]
73 Wang Y, Liu F, Zhang G, Su Y, Sun X, Chen Q, Wang C, Fu H, He Y, Zhu X, Liu X, Lv M, Zhao X, Zhao X, Li Y, Wang Q, Huang X, Zhang X. Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. Sci China Life Sci 2021;64:766-83. [PMID: 32857289 DOI: 10.1007/s11427-020-1788-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Working Group of Chinese Guideline for the Diagnosis and Treatment of Childhood Primary Immune Thrombocytopenia, Subspecialty Group of Hematologic Diseases, Society of Pediatrics, Chinese Medical Association, Editorial Board, Chinese Journal of Pediatrics. Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021). Pediatric Investigation. [DOI: 10.1002/ped4.12305] [Reference Citation Analysis]
75 D'Mello RJ, Hsu CD, Chaiworapongsa P, Chaiworapongsa T. Update on the Use of Intravenous Immunoglobulin in Pregnancy. Neoreviews 2021;22:e7-e24. [PMID: 33386311 DOI: 10.1542/neo.22-1-e7] [Reference Citation Analysis]
76 Sandal R, Mishra K, Jandial A, Sahu KK, Siddiqui AD. Update on diagnosis and treatment of immune thrombocytopenia. Expert Rev Clin Pharmacol 2021;14:553-68. [PMID: 33724124 DOI: 10.1080/17512433.2021.1903315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Viana R, D'Alessio D, Grant L, Cooper N, Arnold D, Morgan M, Provan D, Cuker A, Hill QA, Tomiyama Y, Ghanima W. Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. Adv Ther 2021;38:5791-808. [PMID: 34704193 DOI: 10.1007/s12325-021-01934-0] [Reference Citation Analysis]
78 Moore DC, Elmes JB, Gebru T, Lavery LA, Pellegrino A, Plesca D. Implementation, utilization, and evaluation of a pharmacist-driven romiplostim dosing service for patients with immune thrombocytopenia at a multisite cancer centre. J Oncol Pharm Pract. [DOI: 10.1177/10781552211073763] [Reference Citation Analysis]
79 Ma J, Fu L, Chen Z, Gu H, Ma J, Wu R. High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study. Int J Hematol 2020;112:773-9. [DOI: 10.1007/s12185-020-02977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Stimpson ML, Wolf JS, Williams EL, Lait PJP, Schewitz-Bowers LP, Greenwood R, Pell J, Thomas I, Lee RWJ, Bradbury CA. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. Br J Haematol 2021. [PMID: 34632576 DOI: 10.1111/bjh.17884] [Reference Citation Analysis]
81 Gipson DR, Larkin T, Seifert R, Black LV. Romiplostim as a Therapeutic Intervention for Tacrolimus-induced Immune Thrombocytopenia in a Pediatric Cardiac Transplant Patient. J Pediatr Hematol Oncol 2021;43:e777-9. [PMID: 33181586 DOI: 10.1097/MPH.0000000000001994] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Bussel J, Cooper N, Boccia R, Zaja F, Newland A. Immune thrombocytopenia. Expert Rev Hematol 2021;14:1013-25. [PMID: 34720027 DOI: 10.1080/17474086.2021.1995347] [Reference Citation Analysis]
83 Zhan Y, Cheng L, Wu B, Ji L, Chen P, Li F, Cao J, Ke Y, Yuan L, Min Z, Sun L, Chen H, Hua F, Cheng Y. Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia. Ann Transl Med 2021;9:222. [PMID: 33708849 DOI: 10.21037/atm-20-4729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Yu Y, Wang M, Hou Y, Qin P, Zeng Q, Yu W, Guo X, Wang J, Wang X, Liu G, Chu X, Yang L, Feng Y, Zhou F, Sun Z, Zhang M, Wang X, Wang Z, Ran X, Zhao H, Wang L, Zhang H, Bi K, Li D, Yuan C, Xu R, Wang Y, Zhou Y, Peng J, Liu XG, Hou M. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol 2020;95:1542-52. [PMID: 32871029 DOI: 10.1002/ajh.25989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
85 Lassandro G, Palmieri VV, Barone A, Farruggia P, Giona F, Licciardello M, Marinoni M, Marzollo A, Notarangelo LD, Palumbo G, Ramenghi U, Russo G, Saracco P, Spinelli M, Tolva A, Tornesello A, Palladino V, Noviello D, Giordano P. Fatigue perception in a cohort of children with chronic immune thrombocytopenia and their caregivers using the PedsQL MFS: Real-life multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Pediatr Blood Cancer 2021;68:e28840. [PMID: 33274837 DOI: 10.1002/pbc.28840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Terrell DR, Neunert CE, Cooper N, Heitink-Pollé KM, Kruse C, Imbach P, Kühne T, Ghanima W. Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Kaunas) 2020;56:E667. [PMID: 33266286 DOI: 10.3390/medicina56120667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Vadakkekara J, Mathew R, Khera S. COVID-19-Associated Immune Thrombocytopenia in a Toddler. Indian J Pediatr 2022. [PMID: 35298772 DOI: 10.1007/s12098-022-04109-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Al-Samkari H, Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets 2021;:1-8. [PMID: 33586606 DOI: 10.1080/09537104.2021.1881952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Meyer B, Graf L, Endermann S. [Emergency treatment of severe bleeding in immune thrombocytopenia]. Anaesthesist 2021;70:598-602. [PMID: 33728478 DOI: 10.1007/s00101-021-00939-2] [Reference Citation Analysis]
90 Neunert C. Looking long-term: an unmet need in immune thrombocytopenia. Lancet Haematol 2021;8:e245-6. [PMID: 33770476 DOI: 10.1016/S2352-3026(21)00071-5] [Reference Citation Analysis]
91 Wojciechowski P, Wilson K, Nazir J, Pustułka I, Tytuła A, Smela B, Pochopien M, Vredenburg M, McCrae KR, Jurczak W. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis. Adv Ther 2021;38:3113-28. [PMID: 33934279 DOI: 10.1007/s12325-021-01752-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Li C, Li L, Sun M, Sun J, Shao L, Xu M, Hou Y, Peng J, Wang L, Hou M. Predictive Value of High ICAM-1 Level for Poor Treatment Response to Low-Dose Decitabine in Adult Corticosteroid Resistant ITP Patients. Front Immunol 2021;12:689663. [PMID: 34326842 DOI: 10.3389/fimmu.2021.689663] [Reference Citation Analysis]
93 Wu YJ, Hou M, Liu HX, Peng J, Ma LM, Yang LH, Feng R, Liu H, Liu Y, Feng J, Zhang HY, Zhou ZP, Wang WS, Shen XL, Zhao P, Fu HX, Zeng QZ, Wang XL, Huang QS, He Y, Jiang Q, Jiang H, Lu J, Zhao XY, Zhao XS, Chang YJ, Xu LP, Li YY, Wang QF, Zhang XH. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv 2020;4:5846-57. [PMID: 33232474 DOI: 10.1182/bloodadvances.2020003074] [Reference Citation Analysis]
94 Klompas AM, Boswell MR, Plack DL, Smith MM. Thrombocytopenia: Perioperative Considerations for Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00104-X. [PMID: 33707107 DOI: 10.1053/j.jvca.2021.02.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Song F, Al-Samkari H. Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. J Blood Med 2021;12:653-64. [PMID: 34345191 DOI: 10.2147/JBM.S259101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Kuter DJ. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol 2021. [PMID: 34075578 DOI: 10.1111/bjh.17645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
97 Kochhar M, Neunert C. Immune thrombocytopenia: A review of upfront treatment strategies. Blood Rev 2021;49:100822. [PMID: 33736875 DOI: 10.1016/j.blre.2021.100822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol 2021;8:e229-39. [PMID: 33636143 DOI: 10.1016/S2352-3026(20)30404-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Ma S, Liu A, Hu X, Feng Q, Zhang Y, Li N, Peng J, Sheng Z. Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron. Biochem Pharmacol 2021;186:114436. [PMID: 33539815 DOI: 10.1016/j.bcp.2021.114436] [Reference Citation Analysis]
100 Schmidt DE, Wendtland Edslev P, Heitink-Pollé KMJ, Mertens B, Bruin MCA, Kapur R, Vidarsson G, van der Schoot CE, Porcelijn L, van der Bom JG, Rosthøj S, de Haas M. A clinical prediction score for transient versus persistent childhood immune thrombocytopenia. J Thromb Haemost 2021;19:121-30. [PMID: 33058474 DOI: 10.1111/jth.15125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, Ghanima W, Arnold DM, Tomiyama Y, Santoro C, Michel M, Laborde S, Lovrencic B, Hou M, Bailey T, Taylor-Stokes G, Haenig J, Bussel JB. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol 2021;96:188-98. [PMID: 33170956 DOI: 10.1002/ajh.26045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
102 Newland A, Mcdonald V. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Immunotherapy 2020;12:1325-40. [DOI: 10.2217/imt-2020-0215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Zheng SS, Perdomo JS, Ahmadi Z, Chong BH. Indirect detection of anti-platelet antibodies in immune thrombocytopenia. Pathology 2021:S0031-3025(21)00080-5. [PMID: 33838923 DOI: 10.1016/j.pathol.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Grimes AB, Kim TO, Kirk SE, Flanagan J, Lambert MP, Grace RF, Despotovic JM. Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. Eur J Haematol 2021;106:783-7. [PMID: 33570766 DOI: 10.1111/ejh.13600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Park YH, Kim DY, Kim S, Choi YB, Shin DY, Kim JS, Lee WS, Mun YC, Jang JH, Lee JW, Kook H, Party OBOKAAW. Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Res 2022;57:20-8. [PMID: 35342042 DOI: 10.5045/br.2022.2022043] [Reference Citation Analysis]
106 Caocci G, Efficace F, Mulas O, Cottone F, Maxia A, Costa A, Simula MP, Usala E, La Nasa G. Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy. Ann Hematol. [DOI: 10.1007/s00277-021-04750-2] [Reference Citation Analysis]
107 Al-Samkari H, Cronin A, Arnold DM, Rodeghiero F, Grace RF. Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost 2021;19:2348-54. [PMID: 33974336 DOI: 10.1111/jth.15366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Di Micco P, Camporese G, Cardillo G, Lodigiani C, Carannante N, Annunziata A, Fiorentino G, Russo V, Imbalzano E. Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Kaunas) 2021;57:997. [PMID: 34684034 DOI: 10.3390/medicina57100997] [Reference Citation Analysis]
109 Liu Y, Wang Y, Zhang C, Feng Q, Hou M, Peng J, Hu X, Wang S. HDAC3 single-nucleotide polymorphism rs2530223 is associated with increased susceptibility and severity of primary immune thrombocytopenia. Int J Lab Hematol 2022. [PMID: 35484920 DOI: 10.1111/ijlh.13857] [Reference Citation Analysis]
110 Mingot-Castellano ME, Alcalde-Mellado P, Pascual-Izquierdo C, Perez Rus G, Calo Pérez A, Martinez MP, López-Jaime FJ, Abalo Perez L, Gonzalez-Porras JR, López Fernández F, Caparrós Miranda IS, González-López TJ, Moreno Beltrán ME, Rubio Escuin R, Jimenez Bárcenas R; on behalf GEPTI (Grupo Español de Trombocitopenia Inmune). Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain. Br J Haematol 2021;194:537-41. [PMID: 33991422 DOI: 10.1111/bjh.17506] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Wang T, He X, Ran N, Liu C, Xing L, Wang H, Fu R, Shao Z. Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. J Clin Lab Anal 2021;35:e23922. [PMID: 34329516 DOI: 10.1002/jcla.23922] [Reference Citation Analysis]
112 Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi S, Cheze S, Ghanima W, Tvedt THA, Ebbo M, Terriou L, Bussel JB, Godeau B. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood 2020;136:3056-61. [PMID: 32814348 DOI: 10.1182/blood.2020007594] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
113 Lozano ML, Segú-Vergés C, Coma M, Álvarez-Roman MT, González-Porras JR, Gutiérrez L, Valcárcel D, Butta N. Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. Int J Mol Sci 2021;22:6907. [PMID: 34199099 DOI: 10.3390/ijms22136907] [Reference Citation Analysis]
114 Sheng XY, Liu ZY, Zhao J, Song L, Zhao WM, Zhao X, Cui YM. Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study. Platelets 2022;:1-7. [PMID: 35549802 DOI: 10.1080/09537104.2022.2073344] [Reference Citation Analysis]
115 Sun L, Li L, Sun T, Zhang L, Li C, Xu M, Hou Y, Peng J, Hou M, Wang L. Antihuman CD44 antibody BJ18 inhibits platelet phagocytosis by correcting aberrant FcɣR expression and M1 polarization in immune thrombocytopenia. Int Immunopharmacol 2021;95:107502. [PMID: 33690000 DOI: 10.1016/j.intimp.2021.107502] [Reference Citation Analysis]
116 Snell Taylor SJ, Nielson CM, Breskin A, Saul B, Yu Y, Alam N, Eisen M, Hippenmeyer J, Janssens A, Kozak T, Papadaki HA, Selleslag D, Viallard JF, Feistritzer C, Kaiafa G, Kelsh M, Kilpatrick K, Brookhart MA, McGrath LJ. Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice. Adv Ther 2021;38:2673-88. [PMID: 33866516 DOI: 10.1007/s12325-021-01727-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, Makris M, Newland AC, Provan D, Grainger JD, Hill QA. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 2020;189:1038-43. [PMID: 32374026 DOI: 10.1111/bjh.16775] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
118 Li N, Heddle NM, Nazy I, Kelton JG, Arnold DM. Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia. Blood Adv 2021;5:4256-64. [PMID: 34516622 DOI: 10.1182/bloodadvances.2020004162] [Reference Citation Analysis]
119 Boccia R, Cooper N, Ghanima W, Boxer MA, Hill QA, Sholzberg M, Tarantino MD, Todd LK, Tong S, Bussel JB; FIT Clinical Trial Investigators. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol 2020;190:933-8. [PMID: 33439486 DOI: 10.1111/bjh.16959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
120 Watts A, Raj K, Gogia P, Toquica Gahona CC, Porcelli M. Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19. Cureus 2021;13:e14505. [PMID: 34007758 DOI: 10.7759/cureus.14505] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Tian Z, Gao H, Xiao D, Li X. Immune thrombocytopenia associated with Hashimoto thyroiditis in a pediatric patient: A case report. Medicine (Baltimore) 2021;100:e26140. [PMID: 34087867 DOI: 10.1097/MD.0000000000026140] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Khair K, Pollard D, Steadman L, Jenner K, Chaplin S. The views of women with bleeding disorders: Results from the Cinderella study. Haemophilia. [DOI: 10.1111/hae.14514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Demirci U, Umit EG, Demir AM. A comment on "a prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia" by Zhou et al. Am J Hematol 2020;95:E103-4. [PMID: 31957064 DOI: 10.1002/ajh.25740] [Reference Citation Analysis]
124 Pantić N, Suvajdžić-vuković N. Treating ITP: What are the options in the era of new guidelines and new drugs? Medicinski podmladak 2020;71:40-6. [DOI: 10.5937/mp71-28216] [Reference Citation Analysis]
125 Skopec B, Sninska Z, Tzvetkov N, Ivanushkin V, Björklöf K, Hippenmeyer J, Mihaylov G. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study. Hematology 2021;26:497-502. [PMID: 34238136 DOI: 10.1080/16078454.2021.1948209] [Reference Citation Analysis]
126 Shimano KA, Neunert C, Bussel JB, Klaassen RJ, Bhat R, Pastore YD, Lambert MP, Bennett CM, Despotovic JM, Forbes P, Grace RF. Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. Pediatr Blood Cancer 2021;68:e29023. [PMID: 33764667 DOI: 10.1002/pbc.29023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Zhao P, Hou M, Liu Y, Liu HX, Huang RB, Yao HX, Niu T, Peng J, Jiang M, Han YQ, Hu JD, Zhou H, Zhou ZP, Qiu L, Zhang LS, Wang X, Wang HQ, Feng R, Yang LH, Ma LM, Wang SQ, Kong PY, Wang WS, Sun HP, Sun J, Zhou HB, Zhu TN, Wang LR, Zhang JY, Huang QS, Liu X, Fu HX, Li YY, Wang QF, Jiang Q, Jiang H, Lu J, Zhang XH. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets 2021;32:633-41. [PMID: 32614630 DOI: 10.1080/09537104.2020.1786042] [Reference Citation Analysis]
128 Cooper N, Cuker A, Bonner N, Ghanima W, Provan D, Morgan M, Taylor B, D'Alessio D, Arnold D, Viana R. Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). Br J Haematol 2021;194:759-66. [PMID: 34263940 DOI: 10.1111/bjh.17694] [Reference Citation Analysis]
129 Razanamahery J, Humbert S, Emile JF, Cohen-Aubart F, Fontan J, Maksud P, Audia S, Haroche J. Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review. Front Med (Lausanne) 2021;8:678456. [PMID: 34222286 DOI: 10.3389/fmed.2021.678456] [Reference Citation Analysis]
130 Moulis G, Comont T, Germain J, Sommet A, Lapeyre-Mestre M, Beyne-Rauzy O, Adoue D; CARMEN investigators group. Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. Blood Adv 2020;4:1974-7. [PMID: 32384539 DOI: 10.1182/bloodadvances.2020001664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Abdel Hameed MR, Nafady HA, Mostafa MI, Sayed D, Obiedallah AA. Possible Role of CD11a in Primary Immune Thrombocytopenia Patients on Immunosuppressive Therapy. J Blood Med 2021;12:197-205. [PMID: 33790683 DOI: 10.2147/JBM.S300717] [Reference Citation Analysis]
132 Colella MP, Orsi FA, Alves ECF, Delmoro GF, Yamaguti-Hayakawa GG, de Paula EV, Annichino-Bizzacchi JM. A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response. J Thromb Haemost 2021;19:2275-86. [PMID: 34018665 DOI: 10.1111/jth.15396] [Reference Citation Analysis]
133 Fueyo-Rodriguez O, Valente-Acosta B, Jimenez-Soto R, Neme-Yunes Y, Inclán-Alarcón SI, Trejo-Gonzalez R, García-Salcido MÁ. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination. BMJ Case Rep 2021;14:e242220. [PMID: 34059544 DOI: 10.1136/bcr-2021-242220] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
134 Liu C, Cheng L, Ji L, Li F, Zhan Y, Wu B, Ke Y, Chen P, Hua F, Yuan L, Min Z, Sun L, Chen H, Cheng Y. Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia. Thromb Res 2020;190:11-9. [PMID: 32272276 DOI: 10.1016/j.thromres.2020.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
135 Fu L, Ma J, Gu H, Ma J, Wei Y, Chen Z, Wu R. An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center. Pediatr Blood Cancer 2021;68:e29006. [PMID: 33720524 DOI: 10.1002/pbc.29006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans' Syndrome: From Diagnosis to Treatment. J Clin Med 2020;9:E3851. [PMID: 33260979 DOI: 10.3390/jcm9123851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
137 Rodeghiero F, Cantoni S, Carli G, Carpenedo M, Carrai V, Chiurazzi F, De Stefano V, Santoro C, Siragusa S, Zaja F, Vianelli N. Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic. Mediterr J Hematol Infect Dis 2021;13:e2021032. [PMID: 34007420 DOI: 10.4084/MJHID.2021.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Parodi E, Russo G, Farruggia P, Notarangelo LD, Giraudo MT, Nardi M, Giona F, Giordano P, Ramenghi U, Barone A, Boscarol G, Cesaro S, Fioredda F, Ladogana S, Licciardello M, Rossi F, Rubert L, Spinelli M, Tucci F; “AIEOP-ITP Study Group” (Appendix 1). Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study. Blood Transfus 2020;18:396-405. [PMID: 32931416 DOI: 10.2450/2020.0041-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Nolla M, Aladjidi N, Leblanc T, Fernandes H, Ducassou S, Fahd M, Barlogis V, Michel M, Blouin P, Jeziorski E, Benadiba J, Pondarre C, Leverger G, Pasquet M. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children. Blood 2021;137:138-41. [PMID: 33410895 DOI: 10.1182/blood.2020006807] [Reference Citation Analysis]
140 Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine 2022;76:103820. [PMID: 35074629 DOI: 10.1016/j.ebiom.2022.103820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
141 Kim DS. Recent advances in treatments of adult immune thrombocytopenia. Blood Res 2022;57:112-9. [PMID: 35483935 DOI: 10.5045/br.2022.2022038] [Reference Citation Analysis]
142 Wang L, Li L, Li C, Hou Y, Xu M, Yu Y, Ni X, Wang R, Wang H, Wang L, Peng J, Hou M. Significance of anti-HBc serological status in primary immune thrombocytopenia. Br J Haematol 2021. [PMID: 34854079 DOI: 10.1111/bjh.17977] [Reference Citation Analysis]
143 Iino M, Sakamoto Y, Sato T. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice. Int J Hematol 2020;112:159-68. [DOI: 10.1007/s12185-020-02893-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
144 Deshayes S, Mahévas M, Godeau B. Rituximab and immune thrombocytopenia in adults: The state of knowledge 20 years later. Rev Med Interne 2021;42:32-7. [PMID: 32680716 DOI: 10.1016/j.revmed.2020.05.016] [Reference Citation Analysis]
145 Ansteatt KT, Unzicker CJ, Hurn ML, Olaiya OO, Nugent DJ, Tarantino MD. The Need for Comprehensive Care for Persons with Chronic Immune Thrombocytopenic Purpura. J Blood Med 2020;11:457-63. [PMID: 33364868 DOI: 10.2147/JBM.S289390] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Takami A, Mizuno S, Nakamura A, Kanasugi J, Yamamoto H, Vu Quang L, Nakagami Y, Nakano Y, Yamada S, Matsumura S, Takasugi S, Uchino K, Horio T, Murakami S, Oohigashi Y, Nakayama T, Tani H, Enomoto M, Hanamura I. Pretreatment Immature Platelet Fraction as a Surrogate of Reticulated Platelets Predicts the Response to Corticosteroids in Adults with Immune Thrombocytopenia. Acta Haematol 2021;144:345-9. [PMID: 32942280 DOI: 10.1159/000510460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Hughes DM, Toste C, Nelson C, Escalon J, Blevins F, Shah B. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series. J Adv Pract Oncol 2021;12:508-17. [PMID: 34430061 DOI: 10.6004/jadpro.2021.12.5.6] [Reference Citation Analysis]
148 Walter O, Ribes A, Germain J, Rieu JB, Comont T, Plat A, Rivière B, Deluche L, Delarue L, LeGoff I, Greze M, Dubourdieu B, Rauzy O, Mansat-De Mas V, Moulis G; CARMEN investigators group. Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia. Platelets 2022;:1-6. [PMID: 35348426 DOI: 10.1080/09537104.2022.2053089] [Reference Citation Analysis]
149 Kyrle PA, Eichinger S. How I manage cyclic thrombocytopenia. Blood 2021;137:178-84. [PMID: 33197928 DOI: 10.1182/blood.2020008218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
150 Michel M, Lega JC, Terriou L. [Secondary ITP in adults]. Rev Med Interne 2021;42:50-7. [PMID: 33139079 DOI: 10.1016/j.revmed.2020.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
151 Bussel JB. Early combination treatment of immune thrombocytopenia: Is this the way? Am J Hematol 2020;95:1452-3. [PMID: 33068015 DOI: 10.1002/ajh.26024] [Reference Citation Analysis]
152 Liu XG, Hou M. [Interpretation of the updated international consensus report on the investigation and management of adult primary immune thrombocytopenia (version 2019)]. Zhonghua Xue Ye Xue Za Zhi 2020;41:89-92. [PMID: 32135622 DOI: 10.3760/cma.j.issn.0253-2727.2020.02.001] [Reference Citation Analysis]
153 Huang QS, Liu Y, Wang JB, Peng J, Hou M, Liu H, Feng R, Wang JW, Xu LP, Wang Y, Huang XJ, Zhang XH. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol 2021;8:e688-99. [PMID: 34560012 DOI: 10.1016/S2352-3026(21)00240-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Saburi M, Ogata M, Soga Y, Satou T, Itani K, Kohno K, Nakayama T. Association between Platelet-Associated Immunoglobulin G Levels and Response to Corticosteroid Therapy in Patients with Newly Diagnosed Immune Thrombocytopenia. Acta Haematol 2021;144:528-33. [PMID: 33221796 DOI: 10.1159/000511698] [Reference Citation Analysis]
155 Moulis G, Comont T, Adoue D. New insights into the epidemiology of immune thrombocytopenia in adult patients: Impact for clinical practice. Rev Med Interne 2021;42:11-5. [PMID: 32798089 DOI: 10.1016/j.revmed.2020.05.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Davidova Y, Netyazhenko V, Naumchik A, Kozachishin N, Limanskaya AY. ANALYSIS OF THE PLATELET HEMOSTASIS AMONG PREGNANT WOMEN WITH IMMUNE THROMBOCYTOPENIA. RM 2021. [DOI: 10.37800/rm.3.2021.61-75] [Reference Citation Analysis]
157 Xu J, Zhang X, Feng S, Zhao N, Hu X, Cheng Y, Wu Y, Zhou L, Tong J, Zheng C. Clinical efficacy of high-dose dexamethasone with sequential prednisone maintenance therapy for newly diagnosed adult immune thrombocytopenia in a real-world setting. J Int Med Res 2021;49:3000605211007322. [PMID: 33840249 DOI: 10.1177/03000605211007322] [Reference Citation Analysis]
158 Saito M, Morioka M, Izumiyama K, Mori A, Kondo T. Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia. Cureus 2021;13:e17478. [PMID: 34589366 DOI: 10.7759/cureus.17478] [Reference Citation Analysis]
159 Bull T, Jolley R, Martin-Cabrera P, Thomas W. Autoimmune pancytopenia occurring late after simultaneous pancreas and kidney transplantation. BMJ Case Rep 2020;13:e235851. [PMID: 32900732 DOI: 10.1136/bcr-2020-235851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Mahévas M, Audia S, Viallard JF. [Management of multirefractory immune thrombocytopenia]. Rev Med Interne 2021;42:46-9. [PMID: 33334631 DOI: 10.1016/j.revmed.2020.10.378] [Reference Citation Analysis]
161 Jaime-Pérez JC, Ramos-Dávila EM, Meléndez-Flores JD, Gómez-De León A, Gómez-Almaguer D. Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update. Blood Rev 2021;49:100827. [PMID: 33771403 DOI: 10.1016/j.blre.2021.100827] [Reference Citation Analysis]
162 Choy J, Swe EPP, Shearer A. Amifostine and rituximab in refractory immune thrombocytopaenia: A case series. Vox Sang 2021. [PMID: 34939200 DOI: 10.1111/vox.13226] [Reference Citation Analysis]
163 Janssens A, Selleslag D, Depaus J, Beguin Y, Lambert C. Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society. Acta Clin Belg 2022;77:470-83. [PMID: 33635747 DOI: 10.1080/17843286.2021.1876310] [Reference Citation Analysis]
164 Cirasino L. Recommendations for the treatment of immune thrombocytopenia in adults: a comparison. Blood Coagul Fibrinolysis 2021;32:234-6. [PMID: 33827112 DOI: 10.1097/MBC.0000000000001032] [Reference Citation Analysis]
165 Bussel JB, Kuter D. Preparing patients with immune thrombocytopenia for surgery: what are the options? Lancet Haematol 2020;7:e626-7. [PMID: 32853578 DOI: 10.1016/S2352-3026(20)30253-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Rodeghiero F, Marranconi E. Management of immune thrombocytopenia in women: current standards and special considerations. Expert Rev Hematol 2020;13:175-85. [PMID: 31903814 DOI: 10.1080/17474086.2020.1711729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Lozano Almela ML, Sanz Alonso MÁ, Vicente García V. Reply. Med Clin (Barc) 2021:S0025-7753(21)00644-8. [PMID: 34893333 DOI: 10.1016/j.medcli.2021.09.029] [Reference Citation Analysis]
168 Li C, Sun M, Li R, Wang S, Shao L, Xu M, Yao M, Wang L, Hou M, Feng Q, Peng J. Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM. Br J Haematol 2022. [PMID: 35288929 DOI: 10.1111/bjh.18121] [Reference Citation Analysis]
169 Nguyen SN, Phuong Thao NT, Quynh Van PT, Tran VD. First report on health-related quality of life among children with chronic immune thrombocytopenia in Vietnam. Clinical Epidemiology and Global Health 2021;12:100914. [DOI: 10.1016/j.cegh.2021.100914] [Reference Citation Analysis]
170 Ignatova AA, Suntsova EV, Pshonkin AV, Martyanov AA, Ponomarenko EA, Polokhov DM, Fedorova DV, Voronin KA, Kotskaya NN, Trubina NM, Krasilnikova MV, Uzueva SS, Serkova IV, Ovsyannikova GS, Romanova KI, Hachatryan LA, Kalinina II, Matveev VE, Korsantiya MN, Smetanina NS, Evseev DA, Sadovskaya MN, Antonova KS, Khoreva AL, Zharkov PA, Shcherbina A, Sveshnikova AN, Maschan AA, Novichkova GA, Panteleev MA. Platelet function and bleeding at different phases of childhood immune thrombocytopenia. Sci Rep 2021;11:9401. [PMID: 33931737 DOI: 10.1038/s41598-021-88900-6] [Reference Citation Analysis]
171 Kok EY, Srivaths L, Grimes AB, Vogel TP, Sexson Tejtel SK, Muscal E. Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C) - a case series. Pediatr Hematol Oncol 2021;:1-8. [PMID: 33949910 DOI: 10.1080/08880018.2021.1917737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Han P, Hou Y, Zhao Y, Liu Y, Sun Y, Wang H, Xu P, Li G, Sun T, Hu X, Liu X, Li LZ, Peng J, Zhou H, Hou M. Low-dose decitabine modulates T cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood 2021:blood. [PMID: 33876188 DOI: 10.1182/blood.2020008477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
173 Ni X, Li D, Yuan C, Yu Y, Wang H, Wang L, Yu T, Qin P, Peng J, Hou M, Shi Y, Hou Y. Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study. Am J Hematol 2022;97:440-7. [PMID: 35049070 DOI: 10.1002/ajh.26473] [Reference Citation Analysis]
174 Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Engl J Med 2020;382:e43. [PMID: 32294340 DOI: 10.1056/NEJMc2010472] [Cited by in Crossref: 150] [Cited by in F6Publishing: 111] [Article Influence: 75.0] [Reference Citation Analysis]
175 Clerici B, Birocchi S, Bertinato E, Di Benedetto C, Caberlon S, Cattaneo M, Podda GM. A case of newly diagnosed immune thrombocytopenia in the COVID-19 era. Intern Emerg Med 2020. [PMID: 33180223 DOI: 10.1007/s11739-020-02553-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Cunningham JM, Kessler CM. Immune thrombocytopenia in the elderly: immunosenescent and clinical diversity. Br J Haematol 2021. [PMID: 34873690 DOI: 10.1111/bjh.17976] [Reference Citation Analysis]
177 Sokal A, de Nadaï T, Maquet J, Comont T, Limal N, Michel M, Beyne-Rauzy O, Godeau B, Adoue D, Mahévas M, Moulis G; CARMEN investigators group. Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry. Br J Haematol 2021. [PMID: 34738634 DOI: 10.1111/bjh.17935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Zhao Y, Xu P, Guo L, Wang H, Min Y, Feng Q, Hou Y, Sun T, Li G, Ji X, Qiu J, Peng J, Liu X, Hou M. Tumor Necrosis Factor-α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia. Thromb Haemost 2021;121:767-81. [PMID: 33469903 DOI: 10.1055/s-0040-1722186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Kamal AM, Nabih NA, Rakha NM, Sanad EF. Upregulation of necroptosis markers RIPK3/MLKL and their crosstalk with autophagy-related protein Beclin-1 in primary immune thrombocytopenia. Clin Exp Med 2022. [PMID: 35699825 DOI: 10.1007/s10238-022-00839-8] [Reference Citation Analysis]
180 Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol 2021. [PMID: 34611885 DOI: 10.1111/bjh.17872] [Reference Citation Analysis]
181 Rogier T, Samson M, Mourey G, Falvo N, Magy-Bertrand N, Ouandji S, Picque JB, Greigert H, Mausservey C, Imbach A, Ghesquière T, Voillat L, Caillot D, Deconinck E, Bonnotte B, Audia S. Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. J Clin Med 2020;9:E1998. [PMID: 32630482 DOI: 10.3390/jcm9061998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
182 Jolink AC, Nelson VS, Schipperus MR, Amini SN, Vidarsson G, van der Schoot CE, Porcelijn L, de Haas M, Kapur R. Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia. J Clin Med 2021;10:3403. [PMID: 34362187 DOI: 10.3390/jcm10153403] [Reference Citation Analysis]
183 Cooper N, Hill QA, Grainger J, Westwood JP, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. Acta Haematol 2021;144:418-26. [PMID: 33789275 DOI: 10.1159/000510676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Rui M, Wang Y, Fei Z, Shang Y, Ma A, Li H. Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China. Front Med (Lausanne) 2021;8:657539. [PMID: 33816534 DOI: 10.3389/fmed.2021.657539] [Reference Citation Analysis]
185 Lozano ML, Mingot-castellano ME, Perera MM, Jarque I, Campos-alvarez RM, González-lópez TJ, Carreño-tarragona G, Bermejo N, Lopez-fernandez MF, de Andrés A, Valcarcel D, Casado-montero LF, Alvarez-roman MT, Orts MI, Novelli S, González-porras JR, Bolaños E, López-ansoar E, Orna-montero E, Vicente V. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. Blood Cells, Molecules, and Diseases 2021;86:102505. [DOI: 10.1016/j.bcmd.2020.102505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Uğur MC, Namdaroğlu S, Doğan EE, Turan Erkek E, Nizam N, Eren R, Bilgir O. Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura. Turk J Haematol 2021;38:181-7. [PMID: 34162173 DOI: 10.4274/tjh.galenos.2021.2021.0216] [Reference Citation Analysis]
187 Saettini F, Cattoni A, Redaelli M, Silvestri D, Ferrari GM, Biondi A, Jankovic M, Spinelli M. Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. Acta Paediatr 2021;110:643-51. [PMID: 33025591 DOI: 10.1111/apa.15593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
188 Chaturvedi A, Baig KAM, Rathore YS, Chumber S, Dhawan R, Shelar AA, Chekuri R. Splenectomy for Acute or Persistent Immune Thrombocytopenia: an Overkill or a Necessity. Indian J Surg. [DOI: 10.1007/s12262-021-03206-1] [Reference Citation Analysis]
189 Kapur R. Analysing therapeutic responses in immune thrombocytopaenia: shifting the focus towards immune characteristics. Br J Haematol 2020;189:811-2. [PMID: 31997303 DOI: 10.1111/bjh.16482] [Reference Citation Analysis]
190 Lebowa W, Zdziarska J, Sacha T. Immune Thrombocytopenia: Characteristics of the Population and Treatment Methods-One-Center Experience. Hamostaseologie 2022. [PMID: 35654406 DOI: 10.1055/a-1767-0304] [Reference Citation Analysis]
191 Kapur R. Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists. Br J Haematol 2022. [PMID: 35748239 DOI: 10.1111/bjh.18332] [Reference Citation Analysis]
192 Tsykunova G, Ghanima W. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives. Ther Clin Risk Manag 2022;18:273-86. [PMID: 35386180 DOI: 10.2147/TCRM.S251672] [Reference Citation Analysis]
193 Kuter DJ, Tarantino MD, Lawrence T. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Rev 2021;49:100811. [PMID: 33781612 DOI: 10.1016/j.blre.2021.100811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Gotschalck MA, Nørgaard M, Risbo N, Christiansen CF, Bahmanyar S, Ghanima W, Alam N, Frederiksen H, Nielson CM, Sørensen HT. Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia. Eur J Haematol 2021;107:145-56. [PMID: 33851445 DOI: 10.1111/ejh.13635] [Reference Citation Analysis]
195 Young JR, Vignaly L, O'Connor CM, Czajka CM, Rosenbaum AJ. Perioperative Management of Orthopaedic Patients with Hematologic Disorders: A Critical Analysis Review. JBJS Rev 2020;8:e0001. [PMID: 32487975 DOI: 10.2106/JBJS.RVW.20.00001] [Reference Citation Analysis]
196 Carpenedo M, Baldacci E, Baratè C, Borchiellini A, Buccisano F, Calvaruso G, Chiurazzi F, Fattizzo B, Giuffrida G, Rossi E, Palandri F, Scalzulli PR, Siragusa SM, Vitucci A, Zaja F. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. Ther Adv Hematol 2021;12:20406207211048361. [PMID: 34646432 DOI: 10.1177/20406207211048361] [Reference Citation Analysis]
197 González-López TJ, Provan D. Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP). Adv Ther 2022;39:2287-91. [PMID: 35391624 DOI: 10.1007/s12325-022-02133-1] [Reference Citation Analysis]
198 Ceglie G, Nocentini G, De Gennaro F, Clemente V, Di Mauro M, Palumbo G. Immune thrombocytopenia in two infant cases managed with eltrombopag. Pediatr Blood Cancer 2021;68:e29120. [PMID: 34047051 DOI: 10.1002/pbc.29120] [Reference Citation Analysis]
199 Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, Bartoletti D, Giuffrida G, Magro D, Rivolti E, Esposito D, Podda GM, Palandri F. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol 2022. [PMID: 35201417 DOI: 10.1007/s00277-022-04786-y] [Reference Citation Analysis]
200 Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev 2021;:100909. [PMID: 34815110 DOI: 10.1016/j.blre.2021.100909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Kapur R. Anti-CD44 (Kur)lander hits ITP. Blood 2021;137:1997-9. [PMID: 33856448 DOI: 10.1182/blood.2021011369] [Reference Citation Analysis]
202 McDonald V, Newland A, Morgan M, Wilson K, Nazir J, Maguire P, Geldman E, Wynne T. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). Hematology 2021;26:799-808. [PMID: 34605362 DOI: 10.1080/16078454.2021.1978689] [Reference Citation Analysis]
203 Liu Y, Wu R. Efficient adaptation of high‐quality international guidelines for Chinese children with primary immune thrombocytopenia. Pediatric Investigation. [DOI: 10.1002/ped4.12313] [Reference Citation Analysis]
204 Baur R, Jitschin R, Kharboutli S, Stoll A, Völkl S, Büttner-Herold M, Schmidt D, Rösler W, Mackensen A, Mougiakakos D. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report. J Immunother Cancer 2021;9:e002721. [PMID: 34272307 DOI: 10.1136/jitc-2021-002721] [Reference Citation Analysis]
205 Zhu X, Feng R, Huang Q, Liang M, Jiang M, Liu H, Liu Y, Yao H, Zhang L, Qian S, Yang T, Zhang J, Shen X, Yang L, Hu J, Huang R, Jiang Z, Wang J, Zhang H, Xiao Z, Zhan S, Liu H, Wang X, Chang Y, Wang Y, Kong Y, Xu L, Liu K, Zhang X, Yin C, Li Y, Wang Q, Wang J, Huang X, Zhang X. Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology 2022;13:204062072210952. [DOI: 10.1177/20406207221095226] [Reference Citation Analysis]
206 Gardellini A, Guidotti F, Feltri M, Zancanella M, Maino E, Ambrosiani L, Turrini M. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience. Blood Cells Mol Dis 2021;92:102620. [PMID: 34715450 DOI: 10.1016/j.bcmd.2021.102620] [Reference Citation Analysis]
207 Mei H, Xu M, Yuan G, Zhu F, Guo J, Huang R, Qin J, Lv T, Qin F, Cai H, Yin P, Qin T, Hu Y. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. Br J Haematol 2021. [PMID: 34528239 DOI: 10.1111/bjh.17808] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Hou Y, Wang Y, Liu C, Li S, Peng Y, Dong-dong W, Sa R. The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia. Annals of Medicine 2022;54:132-7. [DOI: 10.1080/07853890.2021.2018486] [Reference Citation Analysis]
209 Wang Z, Zeng Z, Ye L, Zhu X, Pei Y, Wang Y, Zheng L. Impact of target-mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. Br J Clin Pharmacol 2021. [PMID: 34705278 DOI: 10.1111/bcp.15130] [Reference Citation Analysis]
210 Dougherty SC, Lynch AC, Hall RD. Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. Clin Case Rep 2021;9:e04227. [PMID: 34188921 DOI: 10.1002/ccr3.4227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Qu M, Zhou J, Yang SJ, Zhou ZP. Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis. J Int Med Res 2020;48:300060520962348. [PMID: 33115308 DOI: 10.1177/0300060520962348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Hato T, Shimada N, Kurata Y, Kuwana M, Fujimura K, Kashiwagi H, Takafuta T, Murata M, Tomiyama Y. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Adv 2020;4:1648-55. [PMID: 32320469 DOI: 10.1182/bloodadvances.2020001446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
213 Xu P, Zhao Y, Yu T, Yu Y, Ni X, Wang H, Sun L, Han P, Wang L, Sun T, Liu X, Zhou H, Peng J, Hou M, Hou Y, Xu M. Atorvastatin restores imbalance of cluster of differentiation 4 (CD4)+ T cells in immune thrombocytopenia in vivo and in vitro. Br J Haematol 2021. [PMID: 34825359 DOI: 10.1111/bjh.17938] [Reference Citation Analysis]
214 Cooper N, Morrison MA, Vladescu C, Hart ACJ, Paul D, Malik A, Young T, Luqmani A, Atta M, Sharp DJ, Bussel JB, Waldman AD. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. Blood 2020;136:2875-80. [PMID: 32750707 DOI: 10.1182/blood.2020004858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
215 Fillitz M, Dixer B, Keil F. Practical considerations for the management of immune thrombocytopenic purpura. Memo 2021;:1-5. [PMID: 34691269 DOI: 10.1007/s12254-021-00771-9] [Reference Citation Analysis]
216 Wang X, Li F, Li Y, Sun L, Meng Y, Fan X, Wang X, Wu D, Cheng Y, Hua F. Decreased levels of immune-regulatory cytokines in patients with immune thrombocytopenia and long-lasting overexpression of these cytokines in the splenectomized patients. J Leukoc Biol 2021;110:335-41. [PMID: 34318945 DOI: 10.1002/JLB.5AB0521-621RR] [Reference Citation Analysis]
217 Ghanima W, Gernsheimer T, Kuter DJ. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood 2021;137:2736-44. [PMID: 33827138 DOI: 10.1182/blood.2021010968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Vishnu P, Duncan J, Connell N, Cooper N, Lim W, Rodeghiero F, Tomiyama Y, Grace RF, Bakchoul T, Arnold DM; Platelet Immunology Scientific, Standardization Committee. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. J Thromb Haemost 2021;19:287-96. [PMID: 33070448 DOI: 10.1111/jth.15136] [Reference Citation Analysis]
219 Radhakrishnan UP, Al Qaryoute A, Raman R, Jagadeeswaran P. Splenectomy in zebrafish: a new model for immune thrombocytopenia. Platelets 2021;:1-5. [PMID: 33539196 DOI: 10.1080/09537104.2021.1882667] [Reference Citation Analysis]
220 Martincic Z, Skopec B, Rener K, Mavric M, Vovko T, Jereb M, Lukic M. Severe immune thrombocytopenia in a critically ill COVID-19 patient. Int J Infect Dis 2020;99:269-71. [PMID: 32771636 DOI: 10.1016/j.ijid.2020.08.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
221 Zhao Y, Cui S, Wang Y, Xu R. The Extensive Regulation of MicroRNA in Immune Thrombocytopenia. Clin Appl Thromb Hemost 2022;28:10760296221093595. [PMID: 35536600 DOI: 10.1177/10760296221093595] [Reference Citation Analysis]
222 Stimpson ML, Lait PJP, Schewitz‐bowers LP, Williams EL, Thirlwall KF, Lee RWJ, Bradbury CA. IL‐10 and IL‐17 expression by CD4 + T cells is altered in corticosteroid refractory immune thrombocytopenia (ITP). J Thromb Haemost 2020;18:2712-20. [DOI: 10.1111/jth.14970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Lozano ML, Godeau B, Grainger J, Matzdorff A, Rodeghiero F, Hippenmeyer J, Kuter DJ. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Rev Hematol 2020;13:1319-32. [PMID: 33249935 DOI: 10.1080/17474086.2020.1850253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
224 Onisâi M, Vlădăreanu AM, Iordan I, Bumbea H, Găman M, Ciufu C, Voican I, Cîșleanu D, Vasile D, Marinescu C, Nicolescu A, Spînu A, Nistor R, Alexandru A. Primary, secondary or less frequent causes of immune thrombocytopenia: A case report. Exp Ther Med 2021;22:1096. [PMID: 34504550 DOI: 10.3892/etm.2021.10530] [Reference Citation Analysis]
225 Jaime-pérez JC, Aguilar-calderón P, Jiménez-castillo RA, Ramos-dávila EM, Salazar-cavazos L, Gómez-almaguer D. Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center. Ann Hematol 2020;99:2513-20. [DOI: 10.1007/s00277-020-04257-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Audia S, Bonnotte B. Emerging Therapies in Immune Thrombocytopenia. J Clin Med 2021;10:1004. [PMID: 33801294 DOI: 10.3390/jcm10051004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
227 Makharia A, Lakhotia M, Roy B. Primary Evans syndrome in an adult man. BMJ Case Rep 2021;14:e243051. [PMID: 34887288 DOI: 10.1136/bcr-2021-243051] [Reference Citation Analysis]
228 Zhou H, Hou M. A reply to Demirci et al. Am J Hematol 2020;95:E104. [PMID: 31957056 DOI: 10.1002/ajh.25738] [Reference Citation Analysis]
229 Hicks SM, Lee CSM, Ali SA, Choi PY, Gardiner EE. The molecular basis of immune-based platelet disorders. Clin Sci (Lond) 2020;134:2807-22. [PMID: 33140828 DOI: 10.1042/CS20191101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Berrueco R, Sebastián E, Solsona M, González de Pablo J, Ruiz-Llobet A, Mesegué M, Gálvez E, Sevilla J. Secondary immune thrombocytopenia in children: Characteristics and outcome of a large cohort from two Spanish centres. Acta Paediatr 2021;110:1952-8. [PMID: 33460494 DOI: 10.1111/apa.15765] [Reference Citation Analysis]
231 HaemSTAR Collaborators. A single 1 g/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients. Br J Haematol 2021. [PMID: 34859421 DOI: 10.1111/bjh.17692] [Reference Citation Analysis]
232 Hagag NA, El-Agamy OA, Elshanshory MR, Saad MA, El-Hawary EE. Assessment of plasmablast cells in immune thrombocytopenic purpura in children. Pediatr Hematol Oncol 2022;:1-9. [PMID: 35171075 DOI: 10.1080/08880018.2021.2024928] [Reference Citation Analysis]
233 Mancuso S, Carlisi M, Serra N, Napolitano M, Raso S, Consoli U, Palazzolo R, Lanza Cariccio MR, Siragusa S. Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study. J Blood Med 2020;11:251-8. [PMID: 32801981 DOI: 10.2147/JBM.S256620] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Cheng X, Fu L, Ma J, Gu H, Chen Z, Zhao L, Wang X, Wu R. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv 2021;5:3799-806. [PMID: 34605871 DOI: 10.1182/bloodadvances.2020004110] [Reference Citation Analysis]
235 Zitek T, Weber L, Pinzon D, Warren N. Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives. OAEM 2022;Volume 14:25-34. [DOI: 10.2147/oaem.s331675] [Reference Citation Analysis]
236 Moulis G, Germain J, Rueter M, Lafaurie M, Aroichane M, Comont T, Mahévas M, Viallard JF, Chèze S, Ebbo M, Audia S, Leclerc-Teffahi S, Sommet A, Beyne-Rauzy O, Michel M, Godeau B, Lapeyre-Mestre M; CARMEN investigators group. Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study. Am J Hematol 2022;97:E40-4. [PMID: 34779031 DOI: 10.1002/ajh.26404] [Reference Citation Analysis]
237 Althaus K, Faul C, Bakchoul T. New Developments in the Pathophysiology and Management of Primary Immune Thrombocytopenia. Hamostaseologie 2021;41:275-82. [PMID: 33348391 DOI: 10.1055/a-1311-8264] [Reference Citation Analysis]
238 Weingarten SJ, Friedman D, Arora A. Eltrombopag use for refractory immune thrombocytopenia in pregnancy: A case report. Case Rep Womens Health 2021;29:e00281. [PMID: 33437657 DOI: 10.1016/j.crwh.2020.e00281] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Godeau B, Bonnotte B, Michel M. [Challenges and potential solutions in first-line treatments for immune thrombocytopenia in adults]. Rev Med Interne 2021;42:25-31. [PMID: 32713675 DOI: 10.1016/j.revmed.2020.06.018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]